Desmond. J. Fitzgerald
#126,146
Most Influential Person Now
Desmond. J. Fitzgerald's AcademicInfluence.com Rankings
Desmond. J. Fitzgeraldbiology Degrees
Biology
#7980
World Rank
#10985
Historical Rank
Neuroscience
#1079
World Rank
#1121
Historical Rank
Biochemistry
#1134
World Rank
#1251
Historical Rank
Download Badge
Biology
Desmond. J. Fitzgerald's Degrees
- Bachelors Biology University of California, Berkeley
- PhD Biochemistry Stanford University
- Doctorate Medicine Harvard University
Similar Degrees You Can Earn
Why Is Desmond. J. Fitzgerald Influential?
(Suggest an Edit or Addition)Desmond. J. Fitzgerald's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Platelet activation in unstable coronary disease. (1986) (1223)
- Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. (2004) (827)
- Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. (1988) (489)
- Ticlopidine and clopidogrel. (1999) (483)
- The relationship between cyclooxygenase-2 expression and colorectal cancer. (1999) (467)
- Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. (2000) (385)
- Regulation of connexin 43-mediated gap junctional intercellular communication by Ca2+ in mouse epidermal cells is controlled by E- cadherin (1991) (378)
- Tumor promoters inhibit metabolic cooperation in cocultures of epidermal and 3T3 cells. (1979) (321)
- Integration of Proteomics and Genomics in Platelets (2004) (312)
- Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine–aspartate repeat protein SdrE and protein A (2002) (310)
- Recombinant toxins for cancer treatment. (1991) (308)
- 8-Epi PGF2α Generation During Coronary Reperfusion (1997) (262)
- Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. (1987) (262)
- Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. (1990) (241)
- Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease (2007) (220)
- Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. (2005) (209)
- Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers (2006) (205)
- B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. (1991) (204)
- Thromboxane A2 synthesis in pregnancy-induced hypertension (1990) (204)
- Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. (1991) (193)
- Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease (2003) (189)
- Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. (1989) (186)
- Conformation-Specific Blockade of the Integrin GPIIb/IIIa: A Novel Antiplatelet Strategy That Selectively Targets Activated Platelets (2006) (175)
- Identification of the phosphotyrosine proteome from thrombin activated platelets (2002) (174)
- Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. (1990) (172)
- Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. (1989) (171)
- Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. (2001) (170)
- Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. (1989) (169)
- The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. (1990) (159)
- Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. (1990) (157)
- Targeted toxin therapy for the treatment of cancer. (1989) (156)
- Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. (2000) (153)
- Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes: The Lessons From Antagonizing the Cellular Effects of Thrombin–Acute Coronary Syndromes Trial (2011) (147)
- A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. (2002) (147)
- A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. (1987) (145)
- Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. (1989) (143)
- Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. (1987) (142)
- A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins. (1990) (141)
- Dose- and time-dependent antiplatelet effects of aspirin (2006) (140)
- Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. (2003) (139)
- Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis (2003) (138)
- Selective cyclooxygenase-2 inhibition by nimesulide in man. (1998) (135)
- 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. (1997) (135)
- Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. (1988) (134)
- Profound resolution of early atherosclerosis with conjugated linoleic acid. (2006) (131)
- Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets. (1987) (124)
- Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin–Coronary Artery Disease Trial (2011) (123)
- Moderation of the platelet releasate response by aspirin. (2007) (122)
- Pseudomonas exotoxin: chimeric toxins. (1989) (118)
- Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. (1992) (112)
- Milk-derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis. (2017) (111)
- Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma (1994) (106)
- Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen (2001) (106)
- Conserved patterns of bending in satellite and nucleosome positioning DNA. (1994) (103)
- Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. (1988) (102)
- Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. (2010) (98)
- Evidence that the penton base of adenovirus is involved in potentiation of toxicity of Pseudomonas exotoxin conjugated to epidermal growth factor (1984) (98)
- Glycoprotein IIb/IIIa Antagonists Induce Apoptosis in Rat Cardiomyocytes by Caspase-3 Activation* (2000) (94)
- Intravascular Thrombosis After Hypoxia-Induced Pulmonary Hypertension: Regulation by Cyclooxygenase-2 (2004) (94)
- Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. (1999) (92)
- Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. (1986) (91)
- Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. (1988) (90)
- The Platelet Integrin αIIbβ3 Has an Endogenous Thiol Isomerase Activity* (2000) (88)
- Aspirin and clopidogrel resistance. (2007) (87)
- The morphologic pathway of binding and internalization of epidermal growth factor in cultured cells. Studies on A431, KB, and 3T3 cells, using multiple methods of labelling. (1983) (85)
- Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. (1990) (83)
- Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. (1985) (83)
- A Sequence within the Cytoplasmic Tail of GpIIb Independently Activates Platelet Aggregation and Thromboxane Synthesis* (1998) (82)
- Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. (1984) (82)
- Gap-junctional intercellular communication in epidermal cell lines from selected stages of SENCAR mouse skin carcinogenesis. (1989) (82)
- Characterization of immunotoxins active against ovarian cancer cell lines. (1985) (81)
- Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. (1993) (79)
- Regression of pre-established atherosclerosis in the apoE-/- mouse by conjugated linoleic acid. (2003) (78)
- Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv) (1991) (76)
- Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells. (1988) (76)
- Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. (1993) (75)
- Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and cell proliferation in human vascular endothelial cells (2005) (74)
- Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. (1991) (73)
- The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. (1984) (73)
- Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. (1983) (73)
- Changes in gap junction protein (connexin 32) gene expression during rat liver carcinogenesis (1989) (73)
- Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. (1990) (72)
- Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. (1990) (72)
- Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. (2000) (72)
- Inhibition of intercellular communication by tumor-promoting phorbol esters. (1980) (72)
- Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. (1990) (71)
- Reactive oxygen species and platelet activation in reperfusion injury. (1997) (71)
- Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension (2018) (71)
- Role of a low-pH environment in adenovirus enhancement of the toxicity of a Pseudomonas exotoxin-epidermal growth factor conjugate (1984) (70)
- Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. (1991) (70)
- Domain II mutants of Pseudomonas exotoxin deficient in translocation. (1989) (70)
- Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. (1989) (69)
- Aspirin and coronary artery disease (2004) (69)
- Metal complexes of salicylhydroxamic acid (H2Sha), anthranilic hydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)2(Cl)]Cl x H2Sha, a model for a peroxidase-inhibitor complex. (2000) (68)
- Basic calcium phosphate crystal-induced prostaglandin E2 production in human fibroblasts: role of cyclooxygenase 1, cyclooxygenase 2, and interleukin-1beta. (2004) (65)
- Canonical Wnt signaling negatively regulates platelet function (2009) (65)
- Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. (1987) (64)
- 8‐Epi PGF2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo (2003) (64)
- Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). (1991) (63)
- Rapid and reversible inhibition of junctional communication by tumor promoters in a mouse cell line. (1983) (62)
- Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. (1986) (62)
- Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. (1988) (59)
- The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. (1999) (58)
- Phenobarbital specifically reduces gap junction protein mRNA level in rat liver (1988) (58)
- Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer (2009) (58)
- Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)‐dependent proliferation of endothelial cells (EC) via the VEGF‐2 receptor (2001) (58)
- Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. (1993) (57)
- Surface expression of glycoprotein Ibα is dependent on glycoprotein Ibβ: evidence from a novel mutation causing Bernard-Soulier syndrome (2000) (57)
- Milk-derived bioactive peptides inhibit human endothelial-monocyte interactions via PPAR-γ dependent regulation of NF-κB (2015) (56)
- Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. (1991) (55)
- Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. (2001) (55)
- Correlation of probiotic Lactobacillus salivarius growth phase with its cell wall-associated proteome. (2005) (55)
- CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. (1989) (55)
- Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. (1992) (53)
- IL‐10 mediates the immunoregulatory response in conjugated linoleic acid‐induced regression of atherosclerosis (2013) (53)
- Vascular biology of thrombosis: The role of platelet–vessel wall adhesion (2001) (52)
- Tumor promotion: models and assay systems. (1990) (51)
- Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. (1989) (50)
- Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. (1994) (48)
- The Anti-inflammatory Prostaglandin 15-Deoxy-Δ12,14-PGJ2 Inhibits CRM1-dependent Nuclear Protein Export* (2010) (48)
- Potentiation of cytotoxic activity of immunotoxins on cultured human cells. (1985) (48)
- Okadaic acid and phorbol esters: comparative effects of these tumor promoters on cell transformation, intercellular communication and differentiation in vitro. (1990) (48)
- Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity. (1990) (48)
- Role of domain II of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli. (1988) (48)
- Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. (2009) (47)
- Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty (2003) (47)
- Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. (1993) (47)
- Expression and function of connexin in normal and transformed human keratinocytes in culture. (1994) (46)
- Canonical Wnt signaling in megakaryocytes regulates proplatelet formation. (2013) (45)
- Conjugated linoleic acid suppresses the migratory and inflammatory phenotype of the monocyte/macrophage cell. (2010) (45)
- Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid (2013) (45)
- Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. (1992) (44)
- DNA distortion as a factor in nucleosome positioning. (1999) (43)
- Cardiac allograft survival in mice treated with IL-2-PE40. (1989) (43)
- Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. (1996) (43)
- Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. (1999) (43)
- Dietary fish oil accelerates the response to coronary thrombolysis with tissue-type plasminogen activator. Evidence for a modest platelet inhibitory effect in vivo. (1990) (42)
- Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol. (1992) (41)
- Platelet Glycoprotein Ibα Receptor Polymorphisms and Recurrent Ischaemic Events in Acute Coronary Syndrome Patients (2002) (41)
- Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. (1991) (40)
- Unique translational positioning of nucleosomes on synthetic DNAs. (1998) (40)
- Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. (2002) (40)
- Cyclooxygenase-2-Linked Attenuation of Hypoxia-Induced Pulmonary Hypertension and Intravascular Thrombosis (2008) (39)
- Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. (1992) (39)
- Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. (1989) (39)
- The platelet integrin alpha IIbbeta 3 has an endogenous thiol isomerase activity. (2000) (39)
- Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. (1996) (36)
- A proper amino terminus of diphtheria toxin is important for cytotoxicity. (1991) (36)
- Cell-Specific Toxicity of a Chimeric Protein Composed of Interleukin-6 and Pseudomonas Exotoxin (IL6-PE40) on Tumor Cells (1990) (36)
- Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase. (1996) (34)
- Induction of cyclooxygenase‐1 and ‐2 modulates angiogenic responses to engagement of αvβ3 (2003) (34)
- Transdermal Modification of Platelet Function A Dermal Aspirin Preparation Selectively Inhibits Platelet Cyclooxygenase and Preserves Prostacyclin Biosynthesis (1993) (34)
- Enhancement of the activity of immunotoxins by analogues of verapamil. (1989) (33)
- Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin. (1992) (33)
- Detection of non-genotoxic carcinogens in the BALB/c 3T3 cell transformation/mutation assay system. (1989) (33)
- Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. (2013) (33)
- Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation. (1991) (32)
- Effects on intercellular communication in human keratinocytes and liver-derived cells of polychlorinated biphenyl congeners with differing in vivo promotion activities. (1990) (32)
- O-acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme-inhibitor interactions. (2001) (31)
- Metal complexes of salicylhydroxamic acid and O-acetylsalicylhydroxamic acid (1997) (31)
- Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes (1991) (31)
- A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing. (1992) (30)
- Direct cloning and analysis of DNA sequences from a region of the Chinese hamster genome associated with aphidicolin-sensitive fragility. (1998) (30)
- Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. (2006) (30)
- Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. (1992) (30)
- Isolation of human KB cell lines resistant to epidermal growth factor-Pseudomonas exotoxin conjugates. (1987) (30)
- Drug Insight: aspirin resistance—fact or fashion? (2007) (30)
- A novel family of hydroxamate-based acylating inhibitors of cyclooxygenase. (2003) (29)
- Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. (2001) (29)
- Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. (2000) (28)
- Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. (1988) (28)
- Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. (2004) (28)
- Evidence for a differential functional regulation of the two β3-integrins αVβ3 and αIIbβ3 (2006) (28)
- Surface expression of glycoprotein ib alpha is dependent on glycoprotein ib beta: evidence from a novel mutation causing Bernard-Soulier syndrome. (2000) (28)
- Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. (1991) (28)
- Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. (1989) (26)
- 8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. (1996) (26)
- Low pH-induced changes in Pseudomonas exotoxin and its domains: increased binding of Triton X-114 (1990) (26)
- Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. (1997) (26)
- Cyclooxygenase isoforms and atherosclerosis (2003) (25)
- Using proteomics to identify potential therapeutic targets in platelets. (2005) (25)
- Antitumor activity of a thioether-linked immunotoxin: OVB3-PE. (1990) (25)
- Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules. (1990) (25)
- The effect of different strains of Helicobacter pylori on platelet aggregation. (2007) (25)
- Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. (2002) (24)
- Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. (2000) (24)
- Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer (2009) (24)
- Stimulation of adhesion molecule expression by Helicobacter pylori and increased neutrophil adhesion to human umbilical vein endothelial cells (2002) (24)
- Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. (1990) (24)
- Systemic lysis protects against the effects of platelet activation during coronary thrombolysis. (1991) (23)
- Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators. (1991) (23)
- Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. (2006) (23)
- Gap junctional intercellular communication of primary and asbestos-associated malignant human mesothelial cells. (1993) (23)
- Expression of COX-2 and Prognostic Outcome in Uveal Melanoma (2008) (23)
- A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer. (1993) (23)
- The productive conformation of prostaglandin G2 at the peroxidase site of prostaglandin endoperoxide H synthase: docking, molecular dynamics, and site-directed mutagenesis studies. (2006) (23)
- Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes (2004) (23)
- IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. (1990) (22)
- Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3. (2003) (22)
- Determination of aspirin and salicylic acid in transdermal perfusates. (1998) (22)
- Pharmacokinetics of Tissue‐Type Plasminogen Activator During Acute Myocardial Infarction in Men: Effect of a Prostacyclin Analogue (1992) (22)
- Proteomic identification of the candidate target proteins of 15‐deoxy‐delta12,14‐prostaglandin J2 (2013) (22)
- Heterogeneity in the actions of drugs that bind in the DNA minor groove. (1999) (22)
- Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor alpha within Pseudomonas exotoxin as a targeting ligand. (1992) (21)
- Morphological characterization of transformed colonies in rat tracheal epithelial cell cultures exposed to carcinogen. (1986) (21)
- Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions. (1990) (21)
- Cytogenetic changes in rat tracheal epithelial cells during early stages of carcinogen-induced neoplastic progression. (1988) (20)
- IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors. (1988) (20)
- Application of proteomics to the study of platelet regulatory mechanisms. (2004) (20)
- Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. (1994) (20)
- Mechanism of basic calcium phosphate crystal-stimulated matrix metalloproteinase-13 expression by osteoarthritic synovial fibroblasts: inhibition by prostaglandin E2 (2008) (19)
- The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists (2002) (19)
- Mechanism of basic calcium phosphate crystal-stimulated cyclo-oxygenase-1 up-regulation in osteoarthritic synovial fibroblasts. (2008) (18)
- Metsovo-tremolite asbestos fibres: in vitro effects on mutation, chromosome aberration, cell transformation and intercellular communication. (1992) (18)
- Evidence for a differential functional regulation of the two beta(3)-integrins alpha(V)beta(3) and alpha(IIb)beta(3). (2006) (18)
- Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. (1997) (18)
- Targeting growth factor receptors with fusion toxins. (1992) (18)
- Cyclooxygenase-2 inhibitors and atherosclerosis. (2003) (18)
- Pseudomonas exotoxin--immunotoxins. (1988) (18)
- Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice. (1992) (18)
- Substitution of foreign protein sequences into a chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin (1991) (18)
- Growth arrest specific gene (GAS) 6 modulates platelet thrombus formation and vascular wall homeostasis and represents an attractive drug target. (2007) (17)
- Platelet inhibition with an antibody to glycoprotein IIb/IIIa. (1989) (17)
- Isolation of the platelet releasate. (2007) (17)
- A convenient parallel synthesis of low molecular weight hydroxamic acids using polymer-supported 1-hydroxybenzotriazole. (2003) (16)
- Alanine scanning mutagenesis identifies surface amino acids on domain II of Pseudomonas exotoxin required for cytotoxicity, proper folding, and secretion into periplasm. (1992) (16)
- Redirecting Pseudomonas exotoxin. (1991) (16)
- Microsomal prostaglandin E2 synthase 1 expression in basic calcium phosphate crystal-stimulated fibroblasts: role of prostaglandin E2 and the EP4 receptor. (2009) (16)
- Analysis of growth fractions and stem cell compartments in transformed rat tracheal epithelial cell colonies. (1986) (16)
- Helicobacter pylori induces cyclooxygenase‐1 and cyclooxygenase‐2 expression in vascular endothelial cells (2003) (16)
- Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. (1991) (15)
- 15-Deoxy-Δ12,14-Prostaglandin J2 Modifies Components of the Proteasome and Inhibits Inflammatory Responses in Human Endothelial Cells (2016) (15)
- A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. (1991) (15)
- Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients (2000) (14)
- COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy. (2006) (14)
- Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. (1998) (14)
- Cell-type-specific ras mutations but no microsatellite instability in chemically induced mouse skin tumors and transformed 3T3 cells. (1995) (14)
- In vitro analysis of multistage carcinogenesis. (1987) (14)
- Changing responsiveness to all-trans retinoic acid of rat tracheal epithelial cells at different stages of neoplastic transformation. (1986) (14)
- Proteomics Strategy for Identifying Candidate Bioactive Proteins in Complex Mixtures: Application to the Platelet Releasate (2010) (14)
- Gap-junctional communication alterations at various regulatory levels of connexin expression and function during animal and human carcinogenesis (1993) (14)
- Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins. (1987) (14)
- Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. (1991) (14)
- Role of intercellular communication in the control of critical gene expression during multistage carcinogenesis. (1988) (14)
- SorLA modulates atheroprotective properties of CLA by regulating monocyte migration. (2010) (13)
- Analysis of multiple thromboxane metabolites in plasma and urine. (1987) (13)
- Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40. (1991) (13)
- Long-term administration of glycoprotein IIb/IIIa antagonists. (1998) (13)
- Non-steroidal anti-inflammatory drugs (NSAIDs) and gastro-intestinal toxicity: Current issues (1999) (13)
- Platelet function : assessment, diagnosis, and treatment (2005) (13)
- Antiplatelet and anticoagulant therapy during coronary thrombolysis. (1991) (12)
- Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim phamacodynamic results of the SOAR study (1998) (12)
- Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). (2008) (12)
- The impact of genetic variation in the region of the GPIIIa gene, on PlA2 expression bias and GPIIb/IIIa receptor density in platelets (2005) (12)
- A Val193Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand (2001) (11)
- Sequence determinants of DNA bending in the ilvlH promoter and regulatory region of Escherichia coli. (1994) (11)
- Compositional similarities between the human immunodeficiency virus and surface antigens of pathogens. (1996) (11)
- Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity. (2005) (10)
- Clinical applications of immunotoxins. Introduction. (1998) (10)
- A new intercellular communication assay: its use in studies on the mechanism of tumour promotion. (1982) (10)
- Pharmacogenetics of Antiplatelet Drugs (2002) (9)
- Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now? (2003) (9)
- Gap junctional intercellular communication and connexin expression in normal and SV 40-transformed human liver cells in vitro. (1993) (9)
- Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis. (1987) (9)
- 931-113 Demonstration of Potent Inhibition of Platelet Aggregation with an Orally Active GPllb/IIIA Receptor Antagonist (1995) (9)
- Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network. (2005) (8)
- Calreticulin-independent regulation of the platelet integrin αIIbβ3 by the KVGFFKR αIIb-cytoplasmic motif (2004) (8)
- A cold start for oral glycoprotein IIb/IIIa antagonists. (2000) (8)
- Paracetamol poisoning: the action line and the timing of acetylcysteine therapy. (1996) (8)
- Eicosanoids in myocardial ischaemia and injury (1988) (8)
- Fibrinogen receptor and platelet signalling. (1999) (8)
- Impact of genetic variation in the 5-HT transporter and receptor on platelet function in patients with stable CAD taking aspirin. (2016) (7)
- Lack of Bioequivalence Among Low‐dose, Enteric‐coated Aspirin Preparations (2018) (7)
- Engagement of CD 44 modulates cyclooxygenase induction , VEGF generation , and cell proliferation in human vascular endothelial cells (2004) (7)
- Cloning and expression of the H chain V region of antibody OVB3 that reacts with human ovarian cancer. (1988) (7)
- Roleofthrombin andthromboxane A2inreocclusion following coronary thrombolysis withtissue-type plasminogen activator (thrombolytic therapy/coronary thrombosis/platelet activation/reperfusion) (1989) (6)
- Ocular prostaglandin production and morphology in mice lacking a single isoform of cyclooxygenase. (2009) (6)
- Cyclooxygenase-2 expression in primary human colorectal cancers and bone marrow micrometastases. (2004) (6)
- Polymorphisms in glycoprotein (GP) lb alpha are not associated with adverse outcomes in primigravidae. (2000) (6)
- Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). (2018) (5)
- Mechanisms of eicosanoid action. (1991) (5)
- Transdermal aspirin and gastric ulcer healing after coronary artery stent placement. (1996) (5)
- Subcutaneous heparin during coronary thrombolysis. Too little, too late. (1992) (5)
- Biosynthesis of P450 products of arachidonic acid in humans: increased formation in cardiovascular disease. (1991) (5)
- Aspirin resistance and atherothrombotic disease. (2006) (5)
- Helicobacter pylori induces cyclooxygenase-1 as well as cyclooxygenase-2 in endothelial cells (2000) (4)
- Nimesulide, a selective cox-2 inhibitor, causes less gastrointestinal damage compared with naproxen: A prospective study in human volunteers (1998) (4)
- Surgery Induces Cyclooxygenase-2 Expression in the Rat Cervical Spinal Cord (2009) (4)
- A growing set of platelet-activating bacterial proteins. (2002) (4)
- Platelets in Thrombotic and Non-thrombotic Disorders: Monitoring antiplatelet therapy (2002) (4)
- Characterization of a Ligand-attenuated Binding Site on Glycoprotein IIb/IIIa (2002) (4)
- Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim safety and tolerability results of the SOAR study (1998) (4)
- Effect of H. pylori infection on the expression of cyclooxygenase-2 in human gastric mucosa. (2003) (4)
- In vitro and in vivo suppression of interleukin-2-activated killer cell activity by chimeric proteins between interleukin-2 and Pseudomonas exotoxin. (1992) (4)
- TGF alpha-PE40 inhibits non-small cell lung cancer growth. (1994) (4)
- TGF alpha-anti-Tac(Fv)-PE40: a bifunctional toxin cytotoxic for cells with EGF or IL2 receptors. (1990) (3)
- Selective killing of IL6 receptor bearing myeloma cells using recombinant IL6-Pseudomonas toxin. (1990) (3)
- Inhibition of PGE2 Production by Nimesulide Compared with Diclofenac in the Acutely Inflamed Joint of Patients with Arthritis (2012) (3)
- Glycoprotein IIb/IIIa antagonists in acute coronary syndromes. (2001) (3)
- Inhibition of intercellular communication by tumor promoters. (1982) (3)
- A novel use of cardiac pacing to improve cardiac function, quality of life and (hopefully) survival in patients with heart failure and permanent atrial fibrillation (2002) (2)
- Generation of chimeric toxins. (1992) (2)
- Cyclooxygenase Inhibition and P 2 Y 12 Antagonism (2012) (2)
- Warfarin and aspirin after heart-valve replacement. (1994) (2)
- Thromboxane biosynthesis and antagonism in humans. (1987) (2)
- The role of inhibited gap junction function in carcinogenesis (1990) (2)
- Expression of cyclo-oxygenase 2 in colorectal cancer and its relationship to survival (1998) (2)
- Higher Aspirin Dose is Associated with Reduced Mortality and More Serious Bleeding in Patients with Recent Cerebrovascular or Coronary Ischemic Events: Insights from the BRAVO Trial (2003) (1)
- Abstracts of papers presented at the 10th Erfurt conference on platelets, 20–23 June 2004, Augustiner-Kloster, Erfurt, Germany (2004) (1)
- Interaction of antagonists with the platelet GPIIb/IIIa: characterisation of two monoclonal antibodies that detect drug binding (1998) (1)
- Abstract 18596: Conjugated Linoleic Acid Targets {beta}2 Integrin Expression to Suppress Monocyte Adhesion (2012) (1)
- Biosynthesis of thromboxane A2 in renovascular hypertension. (1984) (1)
- PAR2 is partout and now in the heart. (2002) (1)
- Abstract 11072: Profiling of a Platelet Proteome Discriminates Between Subjects and the Effects of Antiplatelet Agents Alone and in Combination (2014) (1)
- Possible Role of Selective Gap Junctional Intercellular Communication in Multistage Carcinogenesis (1)
- Effects of intravenous adenosine on tissue-type plasminogen activator pharmacokinetics in humans (1991) (1)
- Nonlinear binding models suggest that ABCIXIMAB (AB) Pharmacokinetics (PK) and pharmacodynamics (PD) are target‐mediated (2004) (1)
- Regulation of cell cycle progression by cyclooxygenase-2 in colorectal cancer; the role of the EP4 receptor, a novel therapeutic target (2006) (1)
- Irish society of gastroenterology (1998) (1)
- DRAK2 a Novel Effector of Apoptosis is Modulated by Cyclooxygenase 2 in Colorectal Cancer (2004) (0)
- OVINE PGHS-1 COMPLEXED WITH SALICYL HYDROXAMIC ACID (2000) (0)
- Abstract 4002: G-Protein Beta3 Subunit Polymorphism (GNB3 825T) Carriage is Associated with Increased Bleeding in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 Trial (2008) (0)
- Silencing of a death associated protein kinase as a pro-survival factor in colon cancer cells (2005) (0)
- Evidence of transcriptional regulation of the cyclooxygenase-2 promoter by Helicobacter pylori in gastrointestinal cancer cells (2000) (0)
- Stimulation of p-selectin, e-selectin and cellular adhesion molecule expression by H. pylori in endothelial cells mediates increased neutrophil adhesion (2001) (0)
- COX–2 Expression in Human Uveal Melanoma: Implication for Prognosis (2005) (0)
- Utilising proteomics to elucidate signalling pathways in the formation of platelet thrombin: A-559 (2004) (0)
- Effect of H. Pylori infection on the expression of cox-2 in gastric mucosa (1998) (0)
- Generation of anti-inflammatory prostaglandin PGJ2 in inflammatory bowel disease (2003) (0)
- Abstract 130: Il-10 Regulates the Immunoregulatory Response in the Regression of Atherosclerosis (2012) (0)
- The role of platelet–vessel wall adhesion (2001) (0)
- Sequence determinants ofDNAbending intheilvlH promoter andregulatory region ofEscherichia coli (1994) (0)
- Irish society of gastroenterology (1998) (0)
- Thrombosis in the Pathogenesis of Coronary Artery Disease (1998) (0)
- Cox-1 inhibition reduces intimal hyperplasia in vivo (2000) (0)
- Platelet proteome networks: Impact of disease and drugs (2016) (0)
- Production of stable scFv by mutation of the unusual amino acids at the framework region (1998) (0)
- Isoform Specific Disruption of the Cyclooxygenase Genes in Oxygen-induced Retinopathy (2003) (0)
- The MEIS1 Interactome in Megakaryocytes Reveals a Role in Cell Cycle Regulation (2011) (0)
- Cyclooxygenase inhibition in atherothrombotic disease (2008) (0)
- The effect of intravenous adenosine on tissue plasminogen activator pharmacokinetics in man (1991) (0)
- Effect of different strains of Helicobacter pylori on cyclooxygenase-2 promoter activity—Vac A and cag A not involved (2001) (0)
- Chromatin Remodeling Factor ISW1a(del_ATPase) (2011) (0)
- Aggregation and Thromboxane Synthesis GpIIb Independently Activates Platelet A Sequence within the Cytoplasmic Tail of STRUCTURE (2013) (0)
- PO4-100 CONJUGATED LINOLEIC ACID ALTERS THE PRO-ATHEROSCLEROTIC PHENOTYPE OF THE MONOCYTE/MACROPHAGE - EVIDENCE FOR THE INVOLVEMENT OF A NOVEL SIGNALLING PATHWAY (2007) (0)
- The effects of selective cyclo-oxygenase-2 inhibition on postoperative analgesia and prostaglandin formation (2001) (0)
- Mechanisms of H. pylori induced platelet aggregation— Cosignalling between platelet GPIb and FCγRIIa but no role for platelet activating factor (2001) (0)
- The time course of transcriptional regulation of the ‘constitutive’ cyclooxgenase-1 gene by Helicobacter pylori (2001) (0)
- PPARGC1 beta is a genetic determinant of the cardiovascular risk factor, Thromboxane A2-an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) sub-study (2011) (0)
- Theeffects oforganic nitrates on prostacyclin biosynthesis andplatelet function inhumans (1984) (0)
- COX–2 has a Protective Role in a Mouse Model of Ischaemic Retinopathy (2004) (0)
- The Emperor's New Clothes Are Loose: Lower Body Mass Index, Not Calorie Restriction, Accounts for Improved Diastolic Function (2006) (0)
- Effect of inhibition of multiple recognition sites in platelet glycoprotein IIb/IIIa-adhesive proteins interaction (1995) (0)
- protein regulating platelet function Transcription profiling in human platelets reveals LRRFIP1 as a novel (2010) (0)
- 38 b-Adrenoreceptor antagonists and heart failure (2011) (0)
- Milk-derived bioactive peptides inhibit human endothelial-monocyte interactions via PPAR-γ dependent regulation of NF-κB (2015) (0)
- Maree , Fitzgerald : Aspirin and coronary artery disease Platelet aggregation and activation (2017) (0)
- Maree and Fitzgerald PAR 2 Is Partout and Now in the Heart (2002) (0)
- Strain specific Helicobacter pylori induced platelet aggregation: A pivotal role for glycoprotein IB (2000) (0)
- 275 Modulation of PIP2 levels through small molecule inhibition of PIP5K (2014) (0)
- Proteomic analysis of proteins secreted by platelets (2003) (0)
- plasminogen activator Platelet and vascular function during coronary thrombolysis with tissue- type (2011) (0)
- Selected abstracts (2000) (0)
- [Gene cloning, expression of fusion protein TGF alpha-PE 40 and its inhibition activity on cancer cell growth]. (1993) (0)
- Decrease of the tromboxanhalten through the percutaneous administration of the aspirin (1993) (0)
- Eicosenoid biosynthesis in acute myocardial infarction and unstable angina (1985) (0)
- Antagonists of the platelet glycoprotein IIb/IIIa (1995) (0)
- Adjunctive therapy in coronary thrombolysis: prostaglandins, nitrates and calcium antagonists. (1995) (0)
- vascular smooth muscle cells Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating (2011) (0)
- Transcriptional regulation of cyclooxygenase-2 promoter activity in gastrointestinal cancer cells (2000) (0)
- DOUBLING OF ISOPROSTANE FORMATION IN A LARGE COHORT OF HYPERTENSIVE PATIENTS DESPITE OPTIMAL MEDICAL MANAGEMENT.: P 127 (2004) (0)
- Differential expression and regulation of cyclooxygenase-2 in colorectal cancer cells (2000) (0)
- Coronary Heart Disease Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes (2011) (0)
- Differential Expression Of Platelet Proteins In Stable Unstable Coronary Artery Disease and Acute Coronary Syndromes (2013) (0)
- 404-2 Aspirin resistance in cardiovascular disease: underdosing of overweight patients (2004) (0)
- Abstract 43: Activation of the Nuclear Receptor Coactivator PGC-1α Mediates an Atheroprotective Effect (2012) (0)
- aggregation induced platelet - A role for glycoprotein Ib in Streptococcus sanguis (2013) (0)
- Preclinical leads for brain metastases of breast cancer (2008) (0)
- Specific serum antibodies are involved in H. pylori-induced platelet aggregation (2003) (0)
- A partial CURE for acute coronary syndromes--but how did it happen? (2002) (0)
- Tu-W26:1 Platelet contribution to the development of atherosclerosis (2006) (0)
- Highly selective inhibition of platelet glycoprotein gp iib iiia in the setting of coronary thrombolysis (1992) (0)
- Long-term administration of glycoprotein IIb/IIIa (1998) (0)
- Novel Platelet Signalling Pathways Identified via Proteomics (2011) (0)
- Cyclooxygenase 2 inhibition regulates differential expression of gamma catenin(Plakoglobin)in human colon cancer (2003) (0)
- from patients with chronic lymphocytic leukemia monoclonal antibody to the interleukin-2 receptor kill malignant cells Recombinant toxins containing the variable domains of the anti-Tac (2011) (0)
- Chromatin Remodeling Factor ISW1a(del_ATPase) in DNA complex (2011) (0)
- Characterization of Platelet Lipid Rafts Leads to the Identification of RGS-19, Which Forms a Phosphorylation-Dependent Complex with 14-3-3ζ. (2004) (0)
- Evaluating ‘aspirin resistance’ in a population with cardiovascular disease (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Desmond. J. Fitzgerald?
Desmond. J. Fitzgerald is affiliated with the following schools:
